ArticleCureus2025
Clinico-Pathological and Clinical Outcomes of Soft Tissue Sarcoma With FUS-TFCP2 or EWSR1-TFCP2 Fusions: A Case Series From North India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumours with FUS-TFCP2 or EWSR1-TFCP2 mutations are classified under rhabdomyosarcomas at present. These tumours are exceedingly rare and on pathology show spindled to epitheloid cells, with a predisposition for gnathic bone involvement, with an aggressive outcome. We hereby present a total of four patients harbouring a FUS-EWSR1 TFCP2 mutation recruited over a period of 2.5 years. All four reported cases are males with median age of 26.5 years (range 22-37 years). Primary site in all four cases was bone, with three being of head and neck origin and one with a primary in femur. Three of our patients were misdiagnosed outside. All of our patients received chemotherapy at some point and three out of four cases received radiation with a good response (two patients with palliative doses of radiation also responded well). All four patients are alive at follow-up, two on treatment for metastatic disease. This is the first Indian case series reporting the clinicopathological details in patients with TFCP2 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.